• Services

    Services

    Inoviem provides a full range of services from drug discovery to clinical development by leveraging its platforms and direct access to human pathological specimens. All the platforms and services are label free with no modification of the original molecules.

    Understand the mode of action of your compound

    Identify and validate drug-target engagement

    Lead compound optimization

    Patient stratification and biomarkers discovery

    Indication prioritization

    Identify biomarkers and clinical pharmacology

    SPR services 

    MoA Screening

  • Technology

    Technology

    Inoviem provides breakthrough protein technologies for each phase of the drug development process.
    One of the major advantages of our label-free technologies used under physiological conditions and in human tissue – NPOT® and PIMS® – is that the test compound retains its original structure, as well as the exact same molecular structure that would be used in therapy

    Preclinical

    How to best identify the Mode of Action of your compound

    Read more

    From preclinical to clinical

    Ensure Phase II study and success of your drug candidate in Phase III

    Read more

    Clinical

    Successfully identify the cohort of patients who will respond to your therapy

    Read more

  • Expertise

    Our expertise in translational pharmacology

    Inoviem offers translational target discovery and drug-target Mode of Action (MoA) based on proprietary label-free technologies, developed in a pathological and physiological environment, that uses human tissue.

    Translational pharmacology expertise

    Pre-clinical to clinical phases

    Read more

    Our innovative approach

    Biomarkers, patient and therapeutic window

    Read more

    Advantages of approach

    Save time and money

    Read more

    How we work with clients

    Tailored methodologies and technologies 

    Read more

  • Knowledge centre
  • About us

    About us

    Inoviem Scientific is a Bioanalytical R&D company established in 2011 in Strasburg – France.

    Our mission

    Our mission is clear: to get the right treatment to the right patients within the right therapeutic window.

    Read more

    Our team

    • Management team
    • Scientific board
    • Supervisory board & investors

    Read more

  • Contact us
How to identify Hydroxychloroquine’s ON and OFF targets to design a more potent molecule with enhanced clinical efficacy and reduced retinal toxicity in comparison to HCQ?
Email
Print
HYDROXYCHLOROQUINE IDENTITY CARD

Indications

  • Malarial parasites infections
  • Rheumatoid arthritis
  • Discoid or systemic lupus
  • Erythematosus lupus

Side effects

  • Headache
  • Nausea or indigestion
  • Diarrhoea
  • Skin rashes, bleaching of the hair

Pharmacological effect
Exact mechanism of action is unknown

  • erythrocytic dev. of plasmodia
  • pH of the acid vesicles
  • phospholipid metabolism
  • production of rheumatoid factors
  • HCQ is accumulated in white blood cells

Toxicity
Over long period of medication or exposition at high doses, HCQ increases the risk of eye damage, including vision changes and induces rare but irreversible retinopathies (3-5%).1

KEY FIGURES
  • Lupus market: 5 million people throughout the world2
  • Rheumatoid arthritis market: 350 million people worldwide3
INOVIEM SCIENTIFIC ACHIEVEMENTS
  • ON target identification on human lupus PBMCs
  • OFF target identification on mice retina
  • Design of a new molecule that led to a patent application: WO2016193503
  • Efficacy & Safety validation of the new molecule
    • In vitro: Functional/Activity assay, SPR
    • In vivo: 2 mouse models (MRL/lpr & C57Bl/6)
    • Early ADME: Pharmacokinetics
  • Study completed in 9 months
HCQ’S ON & OFF TARGET IDENTIFICATION AND VALIDATION

Peripheral Blood Mononuclear Cell (PBMC) lysates from 20 lupus patients under treatment and retinas from 5 mice were used to perform NPOT® experiments in combination with HCQ, in order to identify HCQ’s ON and OFF targets that could explain its anti-inflammatory activity and retinal toxicity.

This experiment allowed to identify Myeloperoxydase (MPO) as the ON target with occurrence rate of 70%, whereas alphaB-crystallin (αB-C) was identified as the OFF target with occurrence rate of 80%.

MPO has an antimicrobial activity4 and is a key enzyme for neutrophil extracellular trap (NET)5 that explains very well HCQ’s anti-inflammatory properties (figure 1).

Figure 1: The role of MPO on Neutrophil-Mediated Regulation of Immunity (Dragana Odobasic et al. Journal of Immunology Research 2016; ID 2349816)

αB-C is however known to be expressed in many parts of the retina6 and vitreous fluid. Recent studies have shown that αB-C promotes tumor angiogenesis7 and retinal neovascularization8.

The biophysical interaction of HCQ with its targets has been validated by SPR (Biacore 3000®): Kd of 7,1.10-7M on MPO and 2,2.10-8M on its OFF target and functional assay by quantifying HCQ’s influence on the MPO activity (figure 2).

Figure 2: Influence of HCQ concentration on MPO activity

With the aim of loosing the OFF binding interaction, a serie of analogues has been designed and synthesized (in collaboration with the University of Strasbourg, France) based on the chemical structures of MPO and αB-C. The candidate INS-072 has been selected for its enhanced anti-inflammatory properties (INS- 072 EC50 = 6,9.10-9M vs HCQ EC50 = 1,9.10-7M), for its greater efficacy against dermatitis appearance in the MRL/lpr mice model that is known to spontaneously develop Lupus symptoms (figure 3A) and finally for its reduced  emergence of retinopathy (figure 3B) in the C57Bl/6 mice model that is sensible to visual damage.

Figure 3:
A) Representation of the pourcentage of dermatitis appearance over time (in days)
B) Analysis of the cornea Integrity (in pourcentage of retinopathy)

CONCLUSION

Thanks to NPOT®, Inoviem Scientific was capable of identifying and validating, not only HCQ’s ON & OFF targets (Myeloperoxydase and alphaB-crystallin) that explain its unknown mode of action, but also a new drug candidate with a better efficacy and reduced side effect observed on mouse retinas in systemic autoimmune disease.

REFERENCES

  1. 1. Latasiewicz et al. Eye (Lond) 2017; 31(6): 972–976
  2. 2. www.ressources.lupus.org
  3. 3. www.medicinenet.com
  4. 4. https://www.ncbi.nlm.nih.gov/gene?cmd=retrieve&list_uids=4353.
  5. 5. Metzler et al. Blood 2011; 117(3):953-9
  6. 6. Reddy et al. Current molecular medicine 2015; 15:47-61
  7. 7. RDimberg et al. Blood 2008; 111:2015-23
  8. 8. Xu et al. Investigative ophtalmology & visual science 2015; 56:816-26

Description

Headquarter
Bioparc 2, 850 boulevard Sébastien Brant,
67400 Illkirch-Graffenstaden

CONTACT US


SERVICES
EXPERTISE

Our expertise in translational pharmacology
Advantages of a translational pharmacology approach
How we work with clients

TECHNOLOGY

Preclinical
From preclinical to clinical
Clinical

RESOURCES
ABOUT US

Our mission
Our team

PRIVACY POLICY
Need Help